The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of sorafenib and capecitabine for hepatocellular carcinoma in cirrhotic patients.
Yehuda Z. Patt
Research Funding - Bayer
M Houman Fekrazad
No relevant relationships to disclose
Kim A Steinberg
No relevant relationships to disclose
Julie E. Bauman
No relevant relationships to disclose
Sang-Joon Lee
No relevant relationships to disclose
Fa-Chyi Lee
No relevant relationships to disclose